SalterAKowalecKFitzgeraldKC, et al. Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial. Neurology2020; 95(5): e446–e456.
2.
KudrowDPascualJWinnerPK, et al. Vascular safety of erenumab for migraine prevention. Neurology2020; 94(5): e497–e510 (Erratum in: Neurology 2020; 94(23): 1052).
3.
RaghavanKHealyBCCarruthersRL, et al. Progression rates and sample size estimates for PPMS based on the CLIMB study population. Mult Scler2015; 21(2): 180–188.
4.
WaeberCMoskowitzMA. Migraine as an inflammatory disorder. Neurology2005; 64(10 Suppl. 2): S9–S15.
5.
RossettiIZambusiLFinardiA, et al. Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis. J Neuroimmunol2018; 323: 94–104.
